The affinity, intrinsic activity and selectivity of a structurally novel EP 2 receptor agonist at human prostanoid receptors
Authors:
Open Access
- 20 October 2018
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 176 (5) , 687-698
Abstract
Background and Purpose: Prostanoid EP 2 receptor agonists exhibit several activities including ocular hypotension, tocolysis and anti‐inflammatory activity. This report describes the affinity and selectivity of a structurally novel, non‐prostanoid EP 2 receptor agonist, PGN‐9856, and its therapeutic potential. Experimental Approach: The pharmacology of a series of non‐prostanoid EP 2 receptor agonists was determined according to functional and radioligand binding studies, mostly using human recombinant prostanoid receptor transfectants. The selectivity of PGN‐9856, as the preferred compound, was subsequently determined by using a diverse variety of non‐prostanoid target proteins. The therapeutic potential of PGN‐9856 was addressed by determining its activity in relevant primate cell, tissue and disease models. Key Results: PGN‐9856 was a selective and high affinity (pKi ≥ 8.3) ligand at human recombinant EP 2 receptors. In addition to high affinity binding, it was a potent and full EP 2 receptor agonist with a high level of selectivity at EP 1 , EP 3 , EP 4 , DP, FP, IP and TP receptors. In cells overexpressing human recombinant EP 2 receptors, PGN‐9856 displayed a potency (pEC 50 ≥ 8.5) and a maximal response (increase in cAMP) comparable to that of the endogenous agonist PGE 2 . PGN‐9856 exhibited no appreciable affinity (up 10 μM) for a range of 53 other receptors, ion channels and enzymes. Finally, PGN‐9856 exhibited tocolytic, anti‐inflammatory and long‐acting ocular hypotensive properties consistent with its potent EP 2 receptor agonist properties. Conclusions and Implications: PGN‐9856 is a potent, selective and efficacious prostanoid EP 2 receptor agonist with diverse potential therapeutic applications: tocolytic, anti‐inflammatory and notably anti‐glaucoma.Keywords
This publication has 44 references indexed in Scilit:
- Animal research: Reporting in vivo experiments: The ARRIVE guidelinesBritish Journal of Pharmacology, 2010
- Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin‐ethanolamides) in the feline irisBritish Journal of Pharmacology, 2007
- The Prostanoid EP2Receptor Agonist Butaprost Increases Uveoscleral Outflow in the Cynomolgus MonkeyInvestigative Ophthalmology & Visual Science, 2006
- E prostanoid 2 (EP2)/EP4‐mediated suppression of antigen‐specific human T‐cell responses by prostaglandin E2Immunology, 2006
- Prostaglandin E2 is a potent regulator of interleukin‐12‐ and interleukin‐18‐induced natural killer cell interferon‐γ synthesisImmunology, 2004
- Pharmacological Characterization of a Novel Antiglaucoma Agent, Bimatoprost (AGN 192024)The Journal of Pharmacology and Experimental Therapeutics, 2003
- Molecular Characterization and Ocular Hypotensive Properties of the Prostanoid EP 2 ReceptorJournal of Ocular Pharmacology and Therapeutics, 1995
- Pharmacological testing in the laser-induced monkey glaucoma modelCurrent Eye Research, 1985
- Aqueous humour turnover and intraocular pressure during menstruation.British Journal of Ophthalmology, 1984
- Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reactionBiochemical Pharmacology, 1973